Obalon therapeutics inc (OBLN)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14
Operating activities:
Net loss

-23,676

-37,380

-34,765

-20,467

-15,557

-9,890

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

479

581

330

-

-

-

Depreciation, Depletion and Amortization, Nonproduction

-

-

-

192

167

166

Stock-based compensation

2,983

4,693

3,241

563

207

185

Amortization of right-of-use asset

415

0

-

-

-

-

Fair value of stock issued for legal settlements

-

-

1,606

0

0

-

Loss on disposal of fixed assets

-128

-107

0

-13

-19

-5

Change in fair value of warrant liability

-

-

-

466

34

-167

Accretion of investment discount, net

2

50

-18

-125

-260

-64

Amortization of debt discount

70

37

42

70

79

41

Change in operating assets and liabilities:
Accounts receivable, net

-585

-3,353

4,223

0

-96

-83

Accounts receivable from related party

-

-

-515

-121

481

-4

Inventory

-12

162

591

464

-77

166

Other current assets

-411

-98

470

985

-27

109

Accounts payable

-543

70

624

46

370

-

Accounts payable and accrued expenses

-

-

-

-

-

-33

Accrued compensation

-2,985

-689

1,997

1,247

1,018

33

Deferred revenue

72

-158

389

121

0

-

Accrued clinical expenses

-

-

-

-

-

-129

Lease liabilities, net

-364

0

-

-

-

-

Other current and long-term liabilities

-451

68

663

-416

1,009

-

Other current and long-term liabilities

-

-

-

-

-

6

Customer deposit from related party

-

-

-

0

1,283

0

Net cash used in operating activities

-22,866

-29,432

-30,624

-19,368

-11,392

-9,907

Purchases of short-term investments

0

9,102

94,613

18,897

18,590

12,400

Maturities of short-term investments

2,550

29,901

73,800

25,450

21,500

4,250

Sales of short-term investments

-

-

-

-

-

500

Purchases of property and equipment

194

1,282

1,043

352

139

268

Proceeds from disposal of property and equipment

-

-

-

0

6

0

Net cash provided by investing activities

2,356

19,517

-21,856

6,201

2,777

-7,918

Financing activities:
Proceeds from issuance of common stock and warrants, net of issuance costs

23,377

9,823

0

-

-

-

Issuance of preferred stock for cash, net of offering costs

-

-

-

14,517

0

13,622

Issuance of preferred stock to related party for cash

-

-

-

-

-

6,600

Proceeds from initial public offering, net of issuance costs

-

-

-

67,233

0

0

Proceeds from long-term loan, net of issuance costs

10,000

0

-

0

5,000

4,958

Fees paid in connection with fifth amendment to loan and security agreement

0

30

0

30

0

0

Repayments of Long-term Debt

20,000

0

-

-

-

3,000

Proceeds from common stock issued under employee stock purchase plan

0

148

429

0

0

-

Proceeds from sale of common stock upon exercise of stock options

1

53

184

1,066

62

8

Net cash provided by financing activities

13,378

9,994

613

82,786

5,062

22,188

Net (decrease) increase in cash and cash equivalents

-7,132

79

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

-

-

-

0

7

12

Net increase (decrease) in cash and cash equivalents

-

-

-51,867

69,619

-3,546

4,375

Supplemental cash flow information:
Interest paid

719

642

562

-

-

-

Interest paid

-

-

-

527

475

164

Income taxes paid

0

7

2

0

2

1

Conversion of customer deposit from related party to preferred stock

-

-

-

1,283

0

0

Property and equipment in accounts payable

32

201

83

140

0

0

Unpaid issuance costs

0

250

0

-

-

-

Conversion of convertible preferred stock to common stock

-

-

-

70,498

0

0

Fair value of commitment shares issued

0

595

0

591

0

0